KOE:048410

Hyundai Bioscience Co., Ltd. · KOE · Healthcare · KRW · FY for 2025

Figures on this page computed 2026-11-08 13:23 UTC

Last close

n/aKRW

Market data

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed
- Computed from the filing for 2025
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
-629.1%Net margin
Net Income / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
-528.5%FCF margin
Free Cash Flow / Revenue x 100
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
0.16Debt/equity
Total Debt / Shareholders' Equity
Source
computed
Taken on
2026-11-08
Reported in
KRW
- Computed from the filing for 2025
- Computed from the filing for 2025
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-08
Reported in
KRW
- computed

Growth is the furthest below its sector's middle: 0.07 against 0.50 on the market's range.

What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

Five bars, one line

lens 7 of 9

0.19x

2.43x

2.07x

1.02x

n/a

SalesProfitFree cash flowDebtPrice

Each bar against this company's own average; the line is that average.

Computed2025

Market datan/a

Each against its own average

4 of 5 read

Except where said otherwise: Computed from the filing for 2025

Sales0.19x
Its own average over 10 years, 18.70B.
Profit2.43x
Its own average over 10 years, -9.11B.
Free cash flow2.07x
Its own average over 10 years, -9.00B.
Debt1.02x
Its own average over 10 years, 17.54B.
Pricen/a
Its own average over 0 years. Market data

Profit is furthest from its own average, at 2.43 times.

Sales is 0.19 times its own 10-year average; Profit is 2.43 times its own 10-year average; Free cash flow is 2.07 times its own 10-year average; Debt is 1.02 times its own 10-year average.

Every figure in this lens

Except where said otherwise: Computed from the filing for 2025

Sales against its own 10-year average0.19
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Profit against its own 10-year average2.43
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Free cash flow against its own 10-year average2.07
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Debt against its own 10-year average1.02
Source
computed
Statement
income
Fiscal year
2025
Reported in
KRW
Price against its own 0-year averagen/aMarket data
Not held.
Source
market
Reported in
KRW